| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Emily K. Sims | Q87417037 |
| Linda A. DiMeglio | Q57041821 | ||
| P2860 | cites work | Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes | Q77886302 |
| Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes | Q81323909 | ||
| Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes | Q90522551 | ||
| State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018 | Q91108160 | ||
| Beta cells in type 1 diabetes: mass and function; sleeping or dead? | Q91605928 | ||
| DEXI, a candidate gene for type 1 diabetes, modulates rat and human pancreatic beta cell inflammation via regulation of the type I IFN/STAT signalling pathway | Q93383021 | ||
| A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history | Q27334999 | ||
| Lifetime Risk for Diabetes Mellitus in the United States | Q28207985 | ||
| Islet β-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the nonobese diabetic mouse model | Q30421540 | ||
| Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study | Q30502785 | ||
| Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). | Q30505367 | ||
| Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants | Q30557549 | ||
| Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes | Q30574604 | ||
| First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1 diabetes | Q31928474 | ||
| Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method | Q33634067 | ||
| Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants | Q33683763 | ||
| Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset | Q33688616 | ||
| Evidence of beta cell dysfunction which does not lead on to diabetes: a study of identical twins of insulin dependent diabetics | Q34068123 | ||
| Decreased insulin response to glucose in islet cell antibody-negative siblings of type 1 diabetic children | Q34114506 | ||
| The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines | Q34192894 | ||
| Beta cell function in siblings of diabetic children and HLA type | Q35117602 | ||
| β cell death and dysfunction during type 1 diabetes development in at-risk individuals | Q35183950 | ||
| Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. | Q35203692 | ||
| Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease | Q35630698 | ||
| How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited | Q35796906 | ||
| The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. | Q35976782 | ||
| The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes | Q36047238 | ||
| Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. | Q36209699 | ||
| Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial | Q36292592 | ||
| Reduced β-cell function in early preclinical type 1 diabetes | Q36461183 | ||
| Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study | Q36832937 | ||
| Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. | Q36945228 | ||
| The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis | Q37257559 | ||
| Biomarkers of islet beta cell stress and death in type 1 diabetes | Q57129150 | ||
| Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function | Q57491711 | ||
| Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study | Q58037248 | ||
| β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis | Q58792346 | ||
| Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial | Q62587898 | ||
| Diagnosis of pre-type I diabetes | Q68205285 | ||
| Screening for glucose intolerance in siblings of children with diabetes | Q69482120 | ||
| Low acute insulin response to intravenous glucose. A sensitive but non-specific marker of early stages of type 1 (insulin-dependent) diabetes | Q70243695 | ||
| Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies | Q71150178 | ||
| Beta-cell dysfunction in nondiabetic HLA identical siblings of insulin-dependent diabetics | Q71470121 | ||
| Human leukocyte antigen identity and DQ risk alleles in autoantibody-positive siblings of children with IDDM are associated with reduced early insulin response. Childhood Diabetes in Finland (DiMe) Study Group | Q72015340 | ||
| Natural history of preclinical IDDM in high risk siblings. Childhood Diabetes in Finland Study Group | Q72134575 | ||
| Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1 | Q37319146 | ||
| Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years | Q37327047 | ||
| Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association | Q37659402 | ||
| Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation | Q38058245 | ||
| Primary Human and Rat β-Cells Release the Intracellular Autoantigens GAD65, IA-2, and Proinsulin in Exosomes Together With Cytokine-Induced Enhancers of Immunity. | Q38729728 | ||
| TYK2, a Candidate Gene for Type 1 Diabetes, Modulates Apoptosis and the Innate Immune Response in Human Pancreatic β-Cells | Q38846702 | ||
| Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset | Q38991217 | ||
| Prevention and reversal of type 1 diabetes--past challenges and future opportunities | Q39003927 | ||
| Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients. | Q39096821 | ||
| Elevations in the Fasting Serum Proinsulin-to-C-Peptide Ratio Precede the Onset of Type 1 Diabetes | Q39626208 | ||
| The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results | Q40041095 | ||
| Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk | Q40346082 | ||
| Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus | Q40581531 | ||
| Glucose tolerance in siblings of type 1 diabetic patients: relationship to HLA status | Q41449742 | ||
| HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance in families of children with insulin-dependent diabetes mellitus | Q41460874 | ||
| Association of TCF7L2 variation with single islet autoantibody expression in children with type 1 diabetes | Q41751849 | ||
| Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients | Q42477104 | ||
| Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients | Q43245995 | ||
| Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients | Q43300889 | ||
| Serum Insulin and Growth Hormone Response Patterns in Monozygotic Twin Siblings of Patients with Juvenile-Onset Diabetes | Q43534061 | ||
| Effects of insulin in relatives of patients with type 1 diabetes mellitus | Q44010590 | ||
| First-phase insulin response in young healthy children at genetic and immunological risk for Type I diabetes. | Q44253807 | ||
| European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes | Q44814113 | ||
| Insulin resistance is a risk factor for progression to type 1 diabetes | Q45103752 | ||
| Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity | Q45145767 | ||
| Insulin secretion and sensitivity in the prediction of type 1 diabetes in children with advanced β-cell autoimmunity | Q45256653 | ||
| TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. | Q45953659 | ||
| Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. | Q46458859 | ||
| No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins | Q46513469 | ||
| A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. | Q46901921 | ||
| Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). | Q46932751 | ||
| Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. | Q46966748 | ||
| The Melbourne Pre-Diabetes Study: prediction of type 1 diabetes mellitus using antibody and metabolic testing | Q47700755 | ||
| Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials. | Q48144667 | ||
| The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes | Q49691828 | ||
| Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes | Q50077957 | ||
| Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. | Q50787251 | ||
| Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. The Childhood Diabetes in Finland Study Group. | Q51592498 | ||
| Insulin and islet cell autoantibodies as time-dependent covariates in the development of insulin-dependent diabetes: a prospective study in relatives. | Q51599095 | ||
| Elevated proinsulin levels related to islet cell antibodies in first-degree relatives of IDDM patients. | Q51605908 | ||
| Glucose-induced Insulin Response is Reduced and Proinsulin Response Increased in Healthy Siblings of Type 1 Diabetic Patients | Q51610061 | ||
| Increased proinsulin levels as an early indicator of B-cell dysfunction in non-diabetic twins of type 1 (insulin-dependent) diabetic patients. | Q51626329 | ||
| Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose. | Q51641944 | ||
| Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. | Q51646013 | ||
| Beta-cell function and insulin sensitivity in nondiabetic HLA-identical siblings of insulin-dependent diabetics. | Q52593585 | ||
| Glucose-induced insulin response and insulin sensitivity is not related to HLA-type but to age in young siblings of type 1 (insulin-dependent) diabetic patients. | Q54401071 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P921 | main subject | type-1 diabetes | Q124407 |
| insulin-secreting cells | Q70229258 | ||
| P304 | page(s) | S129-S138 | |
| P577 | publication date | 2019-09-01 | |
| P1433 | published in | Molecular Metabolism | Q27724805 |
| P1476 | title | Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes | |
| P478 | volume | 27S |
| Q94600515 | Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure | cites work | P2860 |
Search more.